CDC advisers say they need more evidence to decide if cases of unusual blood clots were linked to the Covid vaccine
Johnson & Johnson’s Covid-19 vaccine will remain in limbo a while longer after US health advisers told the government Wednesday that they need more evidence to decide if a handful of unusual blood clots were linked to the shot – and if so, how big the potential risk really is.
The reports are exceedingly rare – six cases out of more than 7m US inoculations with the one-dose vaccine. But the government recommended a pause in Johnson & Johnson vaccinations this week, not long after European regulators declared that such clots are a rare but possible risk with the AstraZeneca vaccine, a shot made in a similar way but not yet approved for use in the US.
